Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity

Documents similaires

• Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
  par: Iskandar Idris
  Publié: (2024)
• Fenofibrate shown to reduce progression of diabetic retinopathy
  par: Iskandar Idris
  Publié: (2024)
• Epigenetic changes shown to cause type 2 diabetes
  par: Iskandar Idris
  Publié: (2024)
• Increasing excess to weight loss injection shown to save thousands of lives a year
  par: Iskandar Idris
  Publié: (2024)
• Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
  par: Iskandar Idris
  Publié: (2024)